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Spain: The Great Transformation. A
Geographical, Historical, Economic,
and Social Overview
Historical and social perspectives, together with economic
context, are essential to comprehend and appreciate the
current status of any discipline. This is particularly true
for fields relying on technological advances and with
direct effects on society, such as genetics and genomics.
Spain or the Kingdom of Spain, the two denominations
used to designate the country in international treaties, is
a state of southwestern Europe that occupies most of the
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Iberian peninsula, together with Portugal, Gibraltar (an
overseas territory of the United Kingdom), and Andorra,
with archipelagos in the Mediterranean Sea (Balearic
Islands), the Atlantic Ocean (Canary Islands), and the
two cities of Ceuta and Melilla in continental North
Africa. It is the fourth largest (504.645 km²) and sixth
most populated country in Europe (48,146,134 inhabi-
tants in 2015).
Politically, Spain is the youngest Western European
democracy, exerted by a parliamentary government under
a constitutional monarchy. The country has starred in two
of the most extreme moments of Western European history
in the twentieth century: the longest dictatorship in the
modern era of the continent (1939–1975) and the greatest
economic growth in the Eurozone since the creation of the
European Union (1986–2008). In between these periods,
during the so-called ‘Transicion Espa~nola,1 Spain began the
most important sociopolitical progress of its modern his-
tory, starting with the death of the dictator Franco (1975).
The evolution of Spanish society must be analyzed
from political and economic axes. There were three major
periods in the past century of Spanish history: a first stage
of suffering and scarring from the Civil War sank the
country into deep poverty until the end of the autarchic
Franco regime (1939–1958), a second phase of political
and economic opening (1959–1977), and a third stage
toward a fully democratic and parliamentary monarchy
from the adoption of the Spanish Constitution (1978)
until the present.
Franco’s regime was established in 1939 after a 3-year
civil war that shook the entire world and anticipated the
tragedy of the Second World War. This regime halted the
social development of a country that in the first third of
the twentieth century was implementing important struc-
tural changes to replace a failed political regime (la Res-
tauracion2) by another more egalitarian regime
(Republicanism). This political regression led to an eco-
nomic and social downturn, fruit of the limitation of
freedoms, and the obstruction of a rational social life.
From the end of the civil war to the sixties (1939–
1959), Spain lived under an unusually long, politically
isolated, autarchic economic model that caused severe
economic hardship. However, despite the deep recession,
Franco continued the Second Spanish Republic’s attempt
to create a Social Security system (1931) to ensure public
healthcare and protect citizens’ rights to remunerated
retirement. Although it was only a worker’s privilege dur-
ing the early dictatorship, Social Security became a right
extended to all citizens several years later.
In 1959, Spain approved the national Stabilization Plan,
which generated economic liberalization. Despite the dic-
tatorial interventionism, this was the first period of
remarkable socioeconomic progress in the twentieth
century in Spain. Of note, most of Spain’s main univer-
sity hospitals were built from 1960 to 1975.
The next notable moment was the “Moncloa Agree-
ments” (1982), where the various political parties in the
Spanish transition agreed to stabilize the economy as a
sine qua non condition for the modernization of the
country. This paved the way for the third and definitive
boost to the national economy when Spain joined the
European Economic Community in 1986, which later
became the European Union (BBC December 2015; IMF
April 2016) and therefore the EU Common Market. The
major contributors to economic growth were a decrease
in oil prices in the mid-1980s and a massive increase in
foreign investment to expand the infrastructure and tour-
ism of Spain (Gutierrez-Domenech May 2014; BBC
2015), and a Reforma Laboral or Labor Reform. Con-
sumer demand was high in Spain, resulting in many
imports from the EU, but exports remained limited,
which led to a large trade deficit (Beltran 2010).
With the worldwide contraction of the economy in
2008, the Spanish GDP suffered substantially. The con-
struction bubble imploded, resulting in massive job losses
and foreclosures. Unemployment peaked at 26.5% as a
result of economic collapse, with youth unemployment at
56% in 2013 (IMF 2016). In 2010, the government
announced several rounds of unpopular austerity mea-
sures, such as substantial tax increases and wage cuts to
halt the growing deficit (Blanco 2010). Because of fears of
default, the European Commission provided a 40-billion
Euro bailout package to restructure the weakest Spanish
banks in 2012 (Reuters 2010). The public debt increased
from 60.1% of the GDP in 2010 to 101% in 2015, which
may have seriously handicapped Spain’s future growth
and development perspectives. The large underground
economy added to weak, unsolved issues that hampered
competition at the global scale.
Spain’s current GDP of 1,615,074 million places it as
the 16th largest economy worldwide and the 5th largest in
the European Union (data from the International Mone-
tary Fund, 2015). Despite slight signs of slow recovery in
2014 and 2015, it is not obvious whether the levels of
public and private investment and social welfare will
recover to their precrisis mark.
On a positive note, Spain does not suffer from a
regression in the social rights of its citizens. The social
rights of women, or minorities such as homosexuals or
immigrants, are comparable with the most advanced
countries worldwide. We hope that the current genera-
tion, the most educated the country ever had, contributes
to preserve this precious legacy.
Administratively, the Spanish state comprises 17
regions of autonomy, or Autonomous Communities/
Regions (AC/R), and two autonomous cities in North
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Africa (Ceuta and Melilla). AC/R are the first-level
administrative divisions in the country created during the
restoration of democracy at the end of 1979 (see Fig. 1).
The AC/R have wide legislative and executive autonomy
with their own parliaments, although only two AC/R,
Basque country and Navarra, have full fiscal autonomy
for historical reasons. The budget for education, research
and development, and health services is allocated by the
central government, and administered by each AC/R inde-
pendently with authority to decide on the provision of
health services in general, including genetic services and
newborn screening. Nevertheless, there is an Interterrito-
rial Council of the Spanish National Health System that
harmonizes public health services and national strategies
for several health problems, including the National Strat-
egy for Rare Diseases (2015 World Health Report, Annual
Report on the National Health System of Spain 2013,
Informes, Estudios, e Investigacion 2014, Ministerio de
Sanidad Servicios Sociales e Igualdad; CIA The World
Factbook; WHO-Global Health Observatory).
Global healthcare indicators have steadily improved
since 1970. The average life expectancy at birth, 79.3 years
for men and 85.2 years for women (2013), is one of the
highest in the world, and mortality rates have been
decreasing to near the European Union averages. The
neonatal mortality rate per 1000 live births is 2.8 (3.3),
infant mortality is 8 per 1000 live births, and maternal
mortality is 5/100,000 live births (for 413,000 live births
year). The crude death rate per 1000 population is 9.04,
and the top three causes of death in Spain are cardiovas-
cular disease, cancer, and respiratory disease.
The SNS (Sistema Nacional de Salud – National Health
System) care network has a total of 115,200 doctors and
165,000 nurses, mostly employed by hospitals. The SNS
has a network of 453 hospitals, of which 325 are public.
The physician density is 4.95/1000 people, and the total
ratio of available beds is 3.0 for every 1000 inhabitants.
The SNS has 177 Reference Centers, Services, and Units
(CSURS) in 42 healthcare centers to attend to certain
pathologies or perform particularly complex procedures.
Some of these CSURS are concerned with genetic diseases
(www.msssi.gob.es), although the applications for Genet-
ics Clinics and Centers have not been opened yet.
The total expenditure of Spain’s healthcare system is
95,670 million Euros, which represents 9.3% of the
GDP. Of this share, 6.7% is funded by public resources
and 2.6% comes from private resources. Regional gov-
ernments (AC/R), which fund 91.7% of the expenditure,
Figure 1. Territorial organization of Spain in Autonomous Communities or Regions (AC, Comunidades Autonomas).
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bear the greatest burden in the public funding of
healthcare. Curative and rehabilitative care services com-
prise more than half of the total health expenditure
(2015 World Health Report; Annual report on the
National Health System of Spain 2013. Informes, Estu-
dios, e Investigacion 2014. Ministerio de Sanidad Servi-
cios Sociales e Igualdad; CIA The World Factbook;
WHO-Global Health Observatory).
Demographics, Population Diversity,
and Genetics
The population median age is 41.4 years, with 77.4% of
the population living in urban areas. The largest
metropolitan areas are Madrid (6,052,247 inhabitants),
Barcelona (5,030,679), Valencia (1,551, 585), and Seville
(1,294,867).
Spain shows great cultural, religious, and linguistic
diversity, partially because of immigration between 1995
and 2008 during the economic bonanza. Native Spa-
niards, ethnically composed of Mediterranean and Nordic
types, constitute 88% of the current total population. The
rest is composed by a community of around 1 million of
Roma/gypsies and 4.6 million of foreign citizens, originat-
ing mainly from Latin America (39%), North Africa
(16%), Eastern Europe (15%), and Sub-Saharan Africa
(4%) and also Middle Eastern countries as China, Philip-
pines, Pakistan, India, and Bangladesh. The highest num-
ber of immigrant population concentrates in Catalonia,
Madrid, Valencia, and Andalusia. (INE, Estadıstica del
Padron contınuo. www.ine.es).
Regarding official languages, Castillian/Spanish is the
official national language. Catalan is official in Catalonia,
the Balearic islands, and Valencia communities, where it
is known as Valencian. Galician is official in Galicia, Bas-
que is official in the Basque Country and in the Basque
speaking area of Navarra, and Aranese is official in the
northwest corner of Catalonia (Vall d’Aran) along with
Catalan (<5000 speakers).
Roman Catholicism has long been the main religion,
but it no longer has official status by law, and increasing
secularism certifies the decline in the historical influence
of the Catholic Church over the Spanish government.
However, in all public schools, students must choose
either an Ethics or Religion class, and Catholicism is the
only religion officially taught. Today, Spain is religiously
diverse, and there are other religious communities, such
as Protestants, Jehovah’s Witnesses, Mormons, Hindus,
Buddhists, Sikhs, Muslims, and Judaists.
The current birth rate is 9.64 births per 1000 inhabi-
tants and a growth rate of 0.89%. The mean maternal age
is 32 years, and the total fertility rate is 1.49 children
born/woman. Increasing parental age and low fertility
rates suggest social changes, such as the incorporation of
women into the workforce, insufficient measures support-
ing motherhood and family conciliation, gender inequal-
ity, and consequences of the economic crisis.
According to data recorded by the ECEMC (Estudio
Colaborativo Espa~nol de Malformaciones Congenitas), the
percentage of parents of foreign origin rose from 3.5%
from 1980–1997 to 23.19% in 2008, which is expected to
have a direct effect on the ethnic diversity of Spain in
subsequent generations.
Notably, whereas the frequency of newborns with con-
genital defects is 1.4% for the native Spanish population,
the global frequency is 1.52%, being significantly higher
for other ethnic groups, most likely because of difficult
sociosanitary conditions, different genetic substrates, and
a higher number of consanguineous marriages (Bermejo
Sanchez 2010). That study showed a linear decrease in the
frequency of 15 congenital defects from 1980–1985 to
2008. More important decreases (expressed as the fre-
quency of 10,000 newborns) occurred for anencephaly
(4.65–0.28), spina bifida (4.73–0.66), and Down Syn-
drome (14.78–6.41). These results are related to different
variables, including improved pregnancy care (i.e., folic
acid supplementation), an increase in the healthcare cul-
ture of the population, and the voluntary termination of
pregnancies after the detection of fetal abnormalities.
Currently, population registries of congenital defects in
Spain are scarce (Salvador Peral et al. 1998), and it remains
difficult to estimate frequencies of Mendelian disorders. A
successful initiative in this regard was REDEMETH, created
by the National Institute of Health Carlos III, Instituto de
Salud Carlos III, ISCIII, which implemented a 3-year sur-
vey (2003–2005) to collect 1675 cases from 158 different
inborn errors of metabolism, quoting a cumulative inci-
dence of 1 in 800 live births (Pampols 2010). Recently, a
national registry for rare disease was created by the IIER
(Institute for Research in Rare Diseases from the ISCIII)
and integrated into the National Health System (Royal
Decree 1091/2015 from 4 December).
In the past two decades, several studies have been pub-
lished on differential particularities of several rare inher-
ited diseases in the Spanish population: (1) the relatively
high prevalence of mild phenylketonuria (PKU) pheno-
types in Spain compared to Northern European popula-
tions (Desviat et al. 1999); (2) the large mutation
heterogeneity causing cystic fibrosis (CF), for which the
DF 508 mutation accounts for only 48% of CF alleles
compared to 70% in Central and Northern European
Caucasians (Casals et al., 1993); (3) the higher prevalence
of alleles causing autosomal recessive (35delG in conexin
26) or mitochondrial inherited deafness (A1555G in the
12S rRNA) in the Spanish population compared with
Central and Northern European countries (Estivill et al.
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1998; Gasparini et al. 2000); and (4) the high risk of
MCADD, Canavan, and GM1 gangliosidosis in the Roma/
gypsies population (Martınez et al. 1998; Santamarıa et al.
2006) together with the observation of many other reces-
sive disorders in this ethnic group due to high inbreeding
(Lopez-Meseguer et al. 2015; Tenorio et al. 2015).
The use of next generation sequencing (NGS) technolo-
gies has recently confirmed that the allelic frequencies of
variants conferring susceptibility to complex diseases, such
as neuropsychiatric, neurodegenerative, cancer, or type 2
diabetes, are not different from other European populations
(Dopazo et al. 2016). However, the concept of relative
homogeneity within European populations has been ques-
tioned by genome-wide association studies (GWAS), which
report a direct correlation between genetic and geographical
distances (Novembre et al. 2008). Recent research of
Dopazo based on the whole exome sequencing (WES) of
267 healthy Spanish individuals indicated that the level of
variation in local populations, even in the absence of geo-
graphical barriers, is higher than expected from previous
studies based on polymorphisms (Bustamante-Aragones
et al. 2011). A large portion of this variability corresponds
to private variants that confer susceptibility or directly cause
disease in the Spanish population for many Mendelian and
rare diseases, such as hereditary cardiomyopathies, Marfan
syndrome, and degenerative retinal dystrophies (Dopazo
et al. 2016). A recent study aimed to identify individuals
carrying recessive mutations among gamete donors for
reproductive medicine has also contributed to establishing
carrier frequencies for the most common genetic disorders
in Spain (Abulı et al. 2016). Thus, allele frequencies indicate
significant local effects on disease-causing variants that must
be accounted for when vetting candidate variants of Spanish
or Latin-American populations (Dopazo et al. 2016). This
result emphasizes the need for population-specific cata-
logues of genetic variation when attempting diagnoses and
phenotype–genotype correlations. We anticipate that these
approaches will deliver essential information for improving
genetic diagnosis and disease management.
Prenatal diagnosis and prenatal screening
In Spain, the genetic analysis of prenatal samples has fol-
lowed a simple rule from the beginning: it had to be
developed in genetic services already offering postnatal
diagnosis, provided they had acquired technological
expertise and felt comfortable with the interpretation of
fetal samples. The first prenatal cytogenetic diagnostics in
cultured amniocytes were performed in the late 1970s; in
1982, the first biochemical genetic diagnosis was success-
ful. However, when an affected fetus was identified, preg-
nancy termination could not ensue because abortion was
considered a crime until 1985.
In that year, article 417 bis of the penal code was modi-
fied, establishing that abortion would not be penalized in
three situations: (1) if there is risk to the life or health of
the mother; (2) if the fetus is expected to be born with
severe physical or psychic disorders; and (3) rape (Ley
organica 9/1985 de 5 de julio de reforma del artıculo 417
bis del Codigo Penal). In 1986, the Ministerial order of
July 16th provided statistical and epidemiological data on
the voluntary interruption of pregnancy. A Royal Decree
from November 21st of the same year provided data on
the accreditation of centers for the legal practice of volun-
tary interruption of pregnancy. Then, the General Direc-
tion of Public Health of the Ministry of Health developed
a program for prenatal diagnosis that was included in the
National Plan for the prevention of intellectual disability
(Plan Nacional de Prevencion de la Subnormalidad), the
same plan that provided for newborn screening (see
above). At this time, 13/17 of the AC had between 1 and
8 centers of prenatal diagnosis, in which 13,240 kary-
otypes in cultured amniocytes, 1751 studies in amniotic
fluid, 117 in chorion villi, and 6030 consultations of
genetic counseling were performed (Programa de diag-
nostico prenatal. Estudio de los recursos existentes en el area
de genetica. Direccion General de Planificacion Sanitaria.
Ministerio de Sanidad y Consumo, 1986).
In 1987, the Spanish Society for Prenatal Diagnosis
(AEDP) (www.aedprenatal.com) was created, and the first
public health programs for the screening of congenital
defects emerged in the 1990s. This included a triple
screening (biochemical + maternal age + echography, fol-
lowed by karyotype for positive cases) for the detection of
neural tube defects and chromosomal disorders.
In 1997, a survey generated by AEDP analyzed a geo-
graphic area with 342,619 births (total births in Spain
350,000) and showed: (1) important territorial inequali-
ties, in which a geographic area with 117,000 births
remained uncovered by any Public Health Program, and
(2) eight AC/R did not assume perfectly legal abortions
because they conflicted with conscience objection, also
recognized by law. Abortion was selected in 528 cases
with severe congenital defects, which explained only
1.06% of the 49,758 lawful abortions during the identical
period. In two cases, rape occurred, and the physical or
psychological health of the mother (certified by two inde-
pendent psychiatrists) was adduced as the reason for ter-
mination in most cases, a good indicator of complex
underlying social realities (Farran and Pampols 2000).
Important changes occurred in 2010. The Organic Law
2/2010 recognized the right of women to voluntarily
interrupt undesired pregnancies under some conditions:
(1) if it occurs before 14 weeks of pregnancy; (2) the
woman must be previously informed of rights, benefits,
and public help in support of motherhood; and (3) a
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period of at least 3 days must be granted to reconsider
and reflect on information and intervention. The detailed
evaluation of the enforcement of this law shows signifi-
cant data, as the total number of voluntary abortions
decreased from 113,031 to 94,796 in 2010. Undesired
pregnancies accounted for 88.90%, severe risk for the life
or health of the pregnant woman was up to 7.15%, the
risk of severe abnormalities in the fetus was 3.61%, fetal
abnormalities incompatible with life or extremely severe
or untreatable diseases was 0.32%, and other reasons
accounted for 0.01% (Interrupcion voluntaria del embar-
azo. Datos definitivos correspondientes al a~no 2014. Minis-
terio de Sanidad, Seguridad Social e Igualdad). Of note,
the overall frequency of newborns with congenital defects
dropped from 2.22% in 1980–1985 to 1.03% in 2010,
mostly as a result of voluntary termination. However, cer-
tain defects show a secular increase arising from social
causes, such as the progressive increase in parental age.
Ethnic diversification resulting from immigration is also
having an effect (Bermejo Sanchez 2010) (Estudio Colabo-
rativo Espa~nol de Malformaciones Congenitas (ECEMC)
www. Fundacion1000.es).
Prenatal diagnosis using cytogenetics, molecular genet-
ics, and biochemical genetics is regularly performed in the
public health system. New technologies, such as chromo-
somal microarrays (Armengol et al. 2012) and the study
of fetal DNA in maternal plasma, are also being imple-
mented (Bustamante-Aragones et al. 2006). The use of
these and other emerging technologies challenges the cur-
rent prenatal screening strategies (Del Campo Casanelles
et al. 2015; Plaja Rustein et al. 2015) and must be consid-
ered with the analysis of sociohealth conditions when
designing prevention plans for these diseases.
Newborn Screening
Blood-spot newborn screening (NBS) in Spain dates from
1968 to 1969, at which time Pr. Federico Mayor Zaragoza
(who would later be President of UNESCO) at Granada
University and Dr. Joan Sabater at the Institut de Bio-
quımica Clınica in Barcelona began offering NBS for
phenylketonuria and other amino acid disorders using
existing paper chromatography and thin-layer chromatog-
raphy methods. Other centers soon followed this initia-
tive, but the prevention of intellectual disability at the
national level was adopted in 1976 with the creation of
the Real Patronato de Educacion Especial then Real Patron-
ato de Educacion y Atencion a Deficientes under the presi-
dency of Her Majesty Queen Sofıa, who nominated Dr.
Federico Mayor Zaragoza to head the National Program
Plan Nacional de Prevencion de la Subnormalidad. This
plan established objectives in three areas: Metabolic/
Genetic, Nutritional/Pediatric, and Perinatology. The first
area included newborn screening and the diagnosis of
chromosomal abnormalities. After several organizational
changes, the Plan Nacional de Prevencion de la Subnormal-
idad was assumed and financed by the Ministry of Health;
by 1980, there were 10 NBS centers covering 25% of
Spanish newborns and several cytogenetic laboratories in
public hospitals.
Spain’s administrative structure allowed AC/R to inde-
pendently decide what diseases to include in their new-
born screening programs. Until 2000, all autonomous
governments included congenital hypothyroidism (CH)
and PKU. In some AC/R, the program also included,
although not uniformly, congenital adrenal hyperplasia
(CAH), galactosemia (Gal), cystic fibrosis (CF), bio-
tinidase deficiency (BD), and sickle cell disease (SCD).
Large changes arrived in 2001 when Galicia expanded its
program with tandem mass spectrometry (MS/MS), which
was soon followed by Murcia and Andalusia. Other AC/R
delayed the decision to expand programs with MS/MS for
different reasons, such as the lack of cost effectiveness for
such low prevalence diseases in small screening centers,
limited knowledge of medicine-based evidence of benefits,
and low predictive positive value for some diseases.
The situation rapidly evolved, and in 2012, as many as
nine diagnostic centers screened between 2 and 10 diseases,
seven screened between 19 and 28, and three screened
between 32 and 47 (Informe del grupo de expertos sobre con-
crecion de cartera comun de servicios para cribado neonatal.
Ministerio de Sanidad Servicios Sociales e Igualdad. 2012).
Despite disparities on the information received by the
parents, the type of consent, and the magnitude and vol-
ume of processed samples per laboratory or methodology
used, important coincidences were evident: the NBS was
developed as a Public Health Program in all AC/R, being
universally and fairly offered to the whole target popula-
tion; despite not being mandatory, the compliance rate
was nearly 100%. The integrated programs included clini-
cal diagnosis, treatment, and follow up, and they were all
deeply concerned with quality assurance issues, participat-
ing in national and international external quality controls
and were progressively certified under the norm UNE-EN
ISO 15.189.
In 2012, the Interterritorial Council of the Spanish
National Health System updated the Common Portfolio
of Services for the presymptomatic detection of diseases
in the screening population constituted by two working
groups: (1) cancer screening and (2) newborn screening.
The working group for NBS included professionals rep-
resenting AC/R; scientific societies; the Spanish Network
of Technology Evaluation Agencies; and the Ministry of
Health, Social Services, and Equality. The first resolution
was the adoption of criteria to include a disease in a pro-
gram: 18 criteria according to a frame document
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(Documento marco sobre cribado poblacional. Ponencia de
cribado poblacional de la comision de salud publica. Minis-
terio de Sanidad Servicios Sociales e Igualdad. 2010). The
SSI/2065/2014 law from October 13th, 2012 established
that screening for seven diseases must be offered to the
target population in all AC/R: CH, PKU, MCADD (Med-
ium Chain Acyl-CoA Dehydrogenase Deficiency), CF,
SCD, LCHADD (Long-chain L-3 Hydroxyacyl-CoA Dehy-
drogenase Deficiency), and GA type I. Among inherited
metabolic disorders detected by newborn screening, the
most frequent are PKU (1: 18,280) and MCADD (1:
20,158), and the most rare is MADD (Multiple Acyl-
CoA-Dehydrogenase Deficiency (1: 516,793)). Hence, the
incidence of disease was not accounted for as an inclusion
criterion in NBS policy but rather the availability of effi-
cacious treatment and a robust biomarker correlated with
the phenotype. Currently, other diseases are being evalu-
ated for future inclusion in the programs.
The past few years have been characterized by an
increasing awareness of ethical, legal, and social aspects,
which have prompted the publication of documents
with ethical recommendations aiming to promote public
debate in the hopes to contribute to responsible guid-
ance (Abascal et al. 2009; Pampols Ros et al. 2010) and
the enforcement of Law 14/2007 of Biomedical Investi-
gation (LBI). This law aims to encourage biomedical
research while ensuring the highest possible level of
health and ethical guarantees to protect society. There-
fore, it regulates genetic testing and genetic screening in
biomedical research and its healthcare applications.
Other dispositions establish that: (1) the program must
be evaluated by an ethical committee; (2) participation
requires written consent, but consent may be expressed
verbally in exceptional occasions if granted by the ethics
committee; (3) prior information must be written and
shall refer to the voluntary nature of participation; (4)
the quality of screening tests, diagnostic tests, and treat-
ment and follow-up must be ensured with checkpoints
to follow-up on entire programs; (5) the importance of
psychosocial aspects of the program is stressed; (6) the
program must be integrated into the health system; and
(7) the same rules established for genetic testing apply
to the screening tests, which includes the provision of
genetic counseling.
The LBI also regulates the use of human biological
samples for biomedical research. The use of residual
blood-spot samples and associated data for research pur-
poses and their indefinite storage require explicit consent
and an ethical review board. The more frequent situation
is the short storage of residual blood spots, typically 1–
3 years, to permit diagnosis, retesting to confirm results,
post mortem diagnosis, and laboratory audit and quality
control, which do not require explicit consent.
In conclusion, it is currently mandatory by law in Spain
to offer screening for the seven diseases included in the
Common Portfolio of Services, but participation is volun-
tary. NBS is typically conducted without explicit consent
because it is considered to be in the best interest of a child’s
health and part of routine pediatric practice. The more com-
mon situation is an “opt-out” system, whereby screening is
applied unless parents refuse. According to LBI Article 4.
Informed consent and the right to information, the heterozy-
gous state of a recessive disease can be communicated if the
“right not to know” is respected and genetic counseling is
provided. This implies the anticipation of this possible result
in the information provided to the parents and the accep-
tance of the possibility to refuse this information. According
to this article, it could also be inferred that parents have the
right to be informed of incidental results regarding off-tar-
get diseases when they are clinically actionable. Information
on Spanish screening centers, including statistics and disease
incidence, from the beginning of the programs can be
located at the Spanish society for newborn screening
(AECNE) website (www.aecne.es).
Assisted Reproductive Technologies
and Human Genetics
The elaboration of reproductive decisions is a subject in
which the social perspective is deeply rooted in values
and beliefs, and the interface between assisted reproduc-
tive technologies and genetics raises important technical,
social, ethical, and legal issues (Soini et al. 2006).
In Spain, assisted reproduction techniques (ART) are
socially well accepted, legally authorized, and included
within the services offered by the public health system,
although the bulk of activity is performed in private cen-
ters, several with international prestige. According to a
survey by the Spanish Association of Human Genetics
(AEGH), only 5/13 responding centers were public, and
preimplantation genetic diagnosis (PGD) had been per-
formed for 99 different diseases (Informe Situacion del
diagnostico preimplantacional, Comision para el diagnostico
preimplantacional, Julio 2012, www.aegh.org). Instituto
Dexeus, a private center, housed the first baby born after
in vitro fecundation, with Dr. Anna Veiga, currently the
Chairman of the European Society for Human Reproduc-
tion and Embriology (ESHRE). The Register of Centers
and Services in Spain, both public and private, can be
located at www.sefertilidad.net.
Spain is the European country with the most cases of
assisted reproduction, with 17,011 cycles in 2013 (Registry
of the Spanish Society of fertility, www.sefertilidad.net).
Spain is one of the first countries with a law on ART
(Law 35/1988 from November 22 on assisted reproduc-
tion techniques). This law and two other posterior laws
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have been derogated by Law 24/2006 from 28 May with
successive modifications and a consolidated text in 2015
(Ley 14/2006, de 26 de mayo sobre tecnicas de reproduccion
humana asistida, Texto consolidado, Ultima modificacion
14 de julio de 2015).
The law considers that the use of ART and PGD for
embryonic selection applies in the following cases: (1) the
avoidance of severe diseases with early presentation and
without treatment; (2) the avoidance of diseases presenting
at 30–50 years (Huntington Disease, cancers with mild or
high penetrance); and (3) for therapeutic purposes (the
selection of an offspring-compatible donor for a previously
sick child). The two last applications require case-by-case
authorization based on previous reports from the National
Commission of Human Assisted Reproduction (www.cn-
rha.msssi.gob.es). Sperm and oocyte donors should remain
anonymous; this requirement can be waived under excep-
tional circumstances, although this is currently a subject of
ethical and legal debate. Donation must be altruistic, but
economical compensation is allowed to cover alimentary
expenses, travel fees, or loss of working hours, mainly for
oocytes donors. The fate of surplus embryos can be
decided by the woman or couple, including their use for
research purposes. Preimplantation diagnosis for sex selec-
tion is allowed to avoid X-linked diseases but not for social
or family balancing reasons.
There are other legal dispositions relevant for ART,
including Law 16/2003 of Cohesion and Quality of
National Health Service. Law 14/2007 from 13 July of
Biomedical research (LIB) provides legislation on donation
and the use of embryos, fetuses, and cells and tissues from
human embryonic origin, and the Royal Decree Law 9/
2014 from 4 July establishes norms of quality and safety
for the donation, obtainment, evaluation, processing,
preservation, storage, and distribution of human cells and
tissues and approves the norms for the coordination and
functioning of its use in humans. Of note, Spain is one of
the few European countries (together with Greece, Cyprus,
and Poland) in which oocyte donation for women with
advanced maternal age and low ovarian reserve is allowed,
although women must be warned of the risks arising in
pregnancies at clinically advanced age. Concerning the
option for avoiding maternally inherited mutations in
mitochondrial DNA, the so-called “three parent embryo”
is not currently allowed, as the techniques of nuclear trans-
fer with reproductive finalities is not permitted; thus,
oocyte donor programs remain the only current option.
Genetic Services and the New Clinical
Genetics Specialty
The first geneticists in Spain were physicians who intro-
duced Medical Genetics and Cytogenetics to the health
system at the end of the 1960s. Other professionals,
such as biologists and pharmacists, were soon incorpo-
rated into clinical genetic laboratories. However, formal
training in the different clinical genetics figures has
been badly delayed in the country; as a result many
professionals engage in reputed training programs
abroad.
The Spanish Society for the Study of Human Genetics,
currently the AEGH, was created in 1974. At that time,
the society included 66 physicians, 12 biologists, and three
pharmacists. Only 3 years later, there were 128 biologists,
87 physicians, seven pharmacists, and one chemist. In
2002, there were 200 biologists, 97 physicians, 34 pharma-
cists, and 39 professionals from several other fields, such
as chemistry, biochemistry, and biotechnology.
Genetics training was part of pediatrics in medical
school, and laboratory genetics was studied partially in
medicine but also in the faculties of pharmacy, with a
long tradition in clinical analysis and biology.
Of relevance, the Spanish Society of Clinical Genetics
and Dysmorphology (Sociedad Espa~nola de Genetica
Clınica y Dismorfologıa –SEGCD-) is integrated by pedia-
tricians (mostly) and other specialists or health profes-
sionals who work in the clinical genetics units of Spain’s
major hospitals. The society was founded in 1978 as a
Section of the Spanish Association of Pediatrics (AEP)
and in 2002 was credited as an independent Society,
working very closely with the AEGH, sharing knowledge
with the laboratory geneticists and genetic counselors in
order to deliver the standardized excellent care in genetic
diseases to the patients and their families.
The claim for accredited health professionals in the
genetics specialties in Spain is as old as AEGH, with the
first request to health authorities made by its first presi-
dent. Fifteen years later in 1989, AEGH promoted a speci-
fic commission for the specialty, and the National
Commission for Medical Specialties approved the spe-
cialty of genetics. Nevertheless, strong conflicts arose
between physicians and nonphysician professionals, and
the specialty of genetics was paralyzed.
In 1996, the European Society for Human Genetics
launched a European project directed by Professor Harris,
the Concerted Action on Genetic Services in Europe
(CAGSE), in which AEGH actively participated. Accord-
ing to AEGH, there were 40 centers offering cytogenetic
services and 25 offering molecular genetics services. Bio-
chemical genetics services were not recorded, but there
were at least six laboratories offering diagnosis of inborn
errors of metabolism. Seventy-three percent of laborato-
ries were in the public health system, but private centers
began to appear. Nevertheless, the CAGSE project showed
that the clinical genetics situation in Spain was one of the
worst in Europe due partially to the lack of organization
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in the health system and the absence of specific academic
education programs (Genetic Services in Europe, A com-
parative study of 31 countries by the Concerted Action on
Genetic Services in Europe, Editor and Project Leader Rod-
ney Harris. 1997; Ramos-Arroyo et al. 1997).
CAGSE recommended the official recognition of medi-
cal genetics as a medical specialty in Europe, and in 2001,
the European Society for Human Genetics (ESHG) pro-
moted its formal and international recognition. At that
time, the Spanish health system contained important
organizational gaps in genetics, but within 5 years, the
number of centers with molecular genetics services dou-
bled (52 centers/laboratories offering diagnosis for 214
diseases) (Rueda and Briones 2002).
In 2002, the President of AEGH again requested that
the Ministry of Health formally recognize the specialty
but was denied by the National Council for Medical Spe-
cialties. AEGH approved the creation of a new commis-
sion for the specialty coordinated by its President, and
integrated by five professionals with different academic
backgrounds, including medicine, pharmacy, and biology;
multiple years of work in the public health system;
experts in Medical Genetics and Genetic Counseling,
Cytogenetics, Molecular Genetics, and Biochemical Genet-
ics; and on population screening. The AEGH Commission
always offered well-prepared documents, including a pro-
gram proposal for specialty training, and was always pre-
sent in all concerned forums, progressing slowly
(Propuesta razonada para justificar la oportunidad de crear
la especialidad de genetica en el actual Sistema Sanitario
del estado espa~nol, 2005; Propuesta de programa de for-
macion de especialistas en genetica clınica, 2005).
Between 2007 and 2010, important events occurred in
Spain that stressed the effect of human genetics on
healthcare and the need for qualified genetic services:
enforcement of the above-mentioned Law 14/2007 of
Biomedical Investigation (LBI) that among other impor-
tant functions, regulated genetic testing and genetic
screening in biomedical research and healthcare applica-
tions; the launch of the National Strategy for Rare Dis-
eases in the National Health System, indicating that
3,000,000 Spanish citizens could be affected by a rare
genetic disease; Spain became a partner in EUROPLAN,
the European Project for Rare Diseases National Plans
Development; and CIBERER was born (see below).
The importance of LBI for genetic testing must be
stressed: it provides criteria for genetic analysis, including
pertinence, quality, equity, and accessibility; it specifies
that written consent is necessary to undergo genetic anal-
ysis; it recognizes the patient’s right to information and
the “right not to know,” outlining the duty of confiden-
tiality and the right to the protection of genetic data; it
warns against the possibility of unexpected results and the
decision of receiving or not its communication; it cau-
tions that the information obtained may have implica-
tions for family members and when it is appropriate to
convey information to them; and it states the compro-
mise to provide genetic counseling (Pampols et al. 2013).
In Europe, members of Eurogentest Unit 6 and ESHG
Education Committee developed core competencies to
support the preparation of geneticists, and the Committee
of Ministers to Member States adopted recommendation
CM/Rec (2010)11 on the effect of genetics on the organi-
zation of health services and training of health profession-
als. Of the 27 European Union members, Spain was still
the only one without a medical specialization in genetics,
educational courses from an accredited institution for
genetic professionals, or a common organization for
genetic services in the different AC/R (Skirton et al. 2010;
Tejada 2010).
At this time, the Ministry of Health is preparing impor-
tant changes to the training program for medical special-
ties. Many programs will have a 2-year common core for
those specialties sharing affinities before differentiation and
preparation in specific competencies. This reform is a pri-
ority, and new specialties must wait its approval (Proyecto
de Real Decreto por el que se regula la incorporacion de crite-
rios de troncalidad en la formacion de determinadas especiali-
dades en Ciencias de la Salud, La re especializacion troncal y
las areas de capacitacion especıfica, Ministerio de Sanidad,
Polıtica Social e Igualdad, Madrid, 2010). AEGH adapted its
proposal to this scheme (Propuesta razonada para justificar
la oportunidad de crear la especialidad de genetica en el
actual sistema sanitario del estado espa~nol e incorporarla al
sistema de troncalidad. 2007, www.aegh.org, Comision de la
Especialidad).
In 2011, the amending annexes II and V to directive
2005/36/EC of the European Parliament and of the Coun-
cil on the Recognition of Professional Qualifications
included a Clinical Genetics specialty and represented
crucial support (Commission Regulation (EU) No 2013/
2011 of March 2011 amending annexes II and V to Direc-
tive 2005/36/EC of the European Parliament and of the
Council on the Recognition of Professional Qualifica-
tions).
In July 2011, a Project of Royal Decree recognized the
Clinical Genetics specialty (Proyecto de Real Decreto por el
que se crean nuevos tıtulos de especialista y se actualiza el
sistema formativo de determinadas especialidades en cien-
cias de la salud. Ministerio de Sanidad, Polıtica Social e
Igualdad. Madrid, 2011).
In 2012, ESHG recognized Clinical Laboratory Genetics
as an EU-recognized specialist profession, but in Spain,
the Clinical Genetics specialty was unique and assigned
under the umbrella of the professional stem group called
Laboratory and Clinical Diagnosis.
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Finally, in August 2014, a Royal Decree was enforced
with the creation of two new specialties: Child Psychiatry
and Clinical Genetics (Real Decreto 639/2014 de Troncali-
dad y Creacion de Nuevas Especialidades del Sistema
Nacional de Salud en Espa~na). A National Commission
for the Specialty of Clinical Genetics was created to advise
the Ministry of Health. Its nine members, nominated by
different agencies such as Universities, Professional Col-
leges, or Scientific Societies, will have, among others, two
main initial tasks: (1) the preparation of the training pro-
gram for the new residents, and (2) the selection of the
criteria for accreditation of training centers and resident’s
tutors.
In parallel, the European Board of Medical Genetics
(EBMG) is currently working on harmonization, mod-
ernization, and recognition of the specialty at the Euro-
pean Union level, following the scheme of three
professional areas: Clinical Genetics, Laboratory Genetics,
and Genetic Counseling. Spain aims to contribute to this
concerted action for the creation of all three Specialties
in Europe.
While waiting for the first generation of Spanish Clini-
cal Genetics specialists, some AC/R governments have
launched plans for genetics (Plan de Genetica de Andalu-
cia, Plan para el desarrollo de la genetica en la Comunidad
Autonoma del Paıs Vasco, Instruccio 06/2015 Servei Catala
de la Salud). Many academic hospitals in the healthcare
system are organizing new integral and integrated genetic
services with links to research that promote continuous
technological development that is translated to healthcare.
Somatic cell genetics and pharmacogenetics are progress-
ing fields, and a common portfolio of genetic services is
being developed by the Ministry of Health (Orden SSI/
2065/2014 de 13 de Octubre). Actions on rare disease and
the enforcement of Law 14/2007, which calls for the pro-
vision of genetic counseling once the results of the analy-
sis are obtained, have favored education on this aspect,
including the European Master of genetic counseling from
the University “Pompeu i Fabra” and the creation of
SEAGEN, the Spanish Society for Genetic Counselors
(www.seagen.es).
Similar to clinical genetics and despite the increasing
demand of care for patients affected by rare diseases and
cancer, the profession of genetic counselor has not been
yet formally recognized in Spain. In general, genetic
counseling is mainly provided by professionals working in
the established Genetic Services and familial cancer units
along with other medical specialists at the hospitals to
date. Thus, a shortage of trained health professionals in
the field was evident, particularly in light of the rapid
development of genetic and genomic testing.
A specific educational program to train genetic coun-
selors was established during the academic year 2007–
2008 in the life sciences school of the Universitat Pom-
peu Fabra in Barcelona, under the direction and coordi-
nation of medical geneticists trained abroad. This
program, which remains the only training program in
Spain, leads to a Master Degree specialized in Genetic
Counseling. This highly competitive 2-year full-time
program provides a high level of knowledge in both sci-
entific and medical fields, along with the required com-
petences dealing with the psychological, social, and
ethical aspects of genetic counseling. The Master Pro-
gram has been accredited by both the Agency for Qual-
ity of Universities from the National Education Ministry
and by the specific section of the European Board of
Medical Genetics (EBMG, https://www.eshg.org/
408.0.html). Currently, it is one of the only six pro-
grams in Europe that obtained the certification for
training genetic counselors by the EBMG, being also
part of the Transnational Alliance for Genetic Counsel-
ing (TAGC, http://tagc.med.sc.edu/). As a consequence,
although the profession is not yet supported by a legal
framework in Spain, more than 40 genetic counselors
have graduated from the accredited educational program
and are progressively being integrated as full members
on the multidisciplinary teams of many public and pri-
vate Centers dealing with genetic diseases and condi-
tions. In addition, the Spanish Society for Genetic
Counselors was created in 2011 (SEAGEN, www.sea-
gen.es) and is further contributing to the recognition of
the profession. Of note, Spain is currently, along with
France, the European country with more genetic coun-
selors accredited by the EBMG. Spanish genetic coun-
selors are also involved in the evolution of educational
and professional standards in Europe and are working
actively for the certification of genetic counselors as
members of the EBMG.
With the advent of Genomic Medicine, Spain is well
prepared for genomic analysis, with state-of-the-art
public centers, such as the Spanish National Genotyp-
ing Center (www.vsc.es/cenag), Center Nacional
d’Analisi Genomic (www.cnag.cat), and the Genomics
and Bioinformatics Platform of Andalusia (GBPA). The
challenge remains to deliver genomic medicine pro-
mises to the public health system and to ensure high-
quality genetic diagnostic and management as recom-
mended by law (Ley 16/2003 de 28 de mayo de
Cohesion y Calidad del Sistema Nacional de Salud). This
will require the concerted action of political and social
authorities to include WES and WGS in the portfolio
of tests reimbursed by the national health system.
Moreover, current tools for cooperation among Auton-
omous Regions without administrative barriers for the
quality, equity, and accessibility of all Spanish citizens
to a standard-of-care must be improved (Ley 16/2003
385ª 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
T. Pampols et al. Genetics and Genomic Medicine Around The World
de 28 de mayo de Cohesion y Calidad del Sistema
Nacional de Salud).
Research on Clinical Genetics and
Genomics: The CIBERER
To better understand the current challenges faced by the
scientific and medical community in one of Europe’s
youngest democracies, it is useful to gain perspective by
providing a historical note on the fate of Spanish science
in the past 100 years. In the words of Emilio Mu~noz, for-
mer President of the prestigious Consejo Superior de Inves-
tigaciones Cientıficas, CSIC (and Emeritus Research
Professor at the Institute of Philosophy of CSIC): “There
has never been a Spanish golden age of science and tech-
nology. We can only talk about a Spanish silver age
between 1880 and 1936. In this period, Spain was going
through an era of regeneration where education, science,
and technology were promoted by organizations, such as
the Free Education Institution (Institucion Libre de
Ense~nanza) and the Board for advanced studies and scien-
tific research (Junta para Ampliacion de Estudios e Investi-
gaciones Cientıficas – JAE). During this period of change,
the figure of Santiago Ramon y Cajal became a pioneer of
science policy in Spain. To date, he remains the only
Spanish scientist awarded with a Nobel Prize for studies
in Physiology and Medicine performed within Spain.”
The Spanish Civil War (1936–1939) led to the dissolution
of JAE and the exile of many in the academic and scientific
community. As early as 1939, a commission of technocrats
created the National Scientific Research Council (Consejo
Superior de Investigaciones Cientıficas, CSIC) in the first sig-
nificant strategic effort to push modern Spanish science and
technology. This organization was under the control of
Opus Dei, a conservative Catholic institution, which
defended the literalism of the Bible, thus considering Dar-
winism unacceptable. As an example, in the final years of
Franco, religious censors prohibited the great naturalist and
science broadcaster Felix Rodrıguez de la Fuente, also
known abroad as the Spanish Jacques Cousteau, from using
the phrase “the sea, the cradle of life” on public television
(Editorial 2013). Also in the terminal years of the regime, an
attempt to establish the basis for research and development
arrived with the creation of the Technological Institute of
Postgraduates (ITP). This project sought to copy the private
funding model for scientific research of the Massachusetts
Institute of Technology (MIT). Remarkably, the idea did
not get enough support by the first democratic government
of Adolfo Suarez. Finally, the socialist government ended
the project during the 1980s.
After Franco’s death in 1975 and several years of transi-
tion to democracy filled with political tension after a frus-
trated military coup in 1981, some individual initiatives
crystallized upon the arrival of the Socialist Party in govern-
ment in 1982. Spain finally joined the European Commu-
nity in 1986 and started to build a research infrastructure in
alignment with those of more advanced European countries.
In particular, two granting agencies were created, one dedi-
cated to funding fundamental science (MINECO, depend-
ing on the Ministry of Science and Innovation and
mirroring the French CNRS), and the second dedicated to
funding translational and clinical research (Fondo de Investi-
gacion Sanitaria from the Instituto de Salud Carlos III,
depending on the Ministry of Health and Social Policy and
inspired by the French INSERM). In recent decades, the
CSIC has regained the JAE spirit of international exchange
and freedom of thought, reaching a high scientific level.
Technology transfer and innovation in the industrial sector
lagged behind until now, with the economic power in the
country traditionally reluctant to significant investments in
R + D + i. However, a positive trend of increased govern-
mental investment was noticeable in the first years of the
new millennium, until it plateaued in 2008 with 1.9% of the
governmental budget allocated to research. Such efforts,
together with direct funding from the European Commis-
sion, led to the building of prestigious research institutes
and infrastructures (CNIO, PRBB; Barcelona Science Park,
CABIMER, ICFO among others), the consolidation of
national scientists, and the hiring of internationally recog-
nized scientists through highly competitive programs, such
as ICREA or Ikerbasque, to lead a new era and boost scien-
tific production in Spain to positions in accordance with its
demographic and economic weight. This policy was produc-
tive until the unprecedented economic crash of 2008
resulted in a sudden, draconian cut of 40% of research
funds, which is sustained today. Structural damage to all
research bodies ensued, which many believe is nearly irre-
versible (Moro-Martin 2012, 2014), along with other auster-
ity measures that affected even the crown jewel, the public
hospitals and diagnostic services belonging to the National
Health System, who depend largely on funds managed by
the AC/R. Many large hospitals across the country had to
close entire floors and operation rooms and saw the waiting
list for essential interventions increase dangerously. Cur-
rently, the Spanish government has not recovered from the
crisis and dedicates a meager 1.3% of its budget to research
(2013). This is far from the 2% investment of traditionally
wealthier countries, such as the USA, Switzerland, Germany,
or Northern European countries; even farther from the
desirable goal of 3% proposed at Lisbon’s Treaty in 2009;
and below the average of 1.4% in the Eurozone (see Eurostat
data for 2014).
This confirms that the importance of science, technol-
ogy, and innovation as drivers of social and economic
progress is not fully recognized by policy makers, differ-
ing from more advanced countries worldwide. Critical
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voices noted that the unprecedented growth from 1995 to
2007, largely due to an increase in consumer needs and a
massive housing and construction bubble, did not lead to
investments in long-term policies to favor research, devel-
opment, or the industrial sector but rather to further
expand the solid tourism infrastructures and tertiary sec-
tor, thus resulting in a large quantity of low-quality, vola-
tile jobs. Furthermore, the minimum requirement of an
independent commission of scientific experts to assist
Congress on scientific, technologic, and innovation poli-
cies remains absent. The Ministry of Science has also
recently disappeared, being currently reduced to a sec-
ondary branch of the Ministry of Economy. Thus, beyond
a lack of funding, the necessary structures required to
ensure a stable, long-term framework to make science
and innovation the central axes of a more robust and sus-
tainable model of economic growth and social welfare are
simply not yet in place.
In this grim scenario, a light appeared. A public consor-
tium called CIBERER (Center for Network Research on
Rare Diseases) emerged in 2006 under the auspices of the
Spanish National Institute of Health Carlos III (ISCIII),
right before the global economic crash. This innovative
research structure is a member of a broader umbrella com-
prising another 11 consortia dedicated to the main priori-
ties in the National Health System, such as Obesity and
Nutrition, Diabetes and Metabolic Disease, Hepatic and
Digestive Disease, Respiratory Diseases, Epidemiology and
Preventive Medicine, Mental Health, Neurodegenerative
Diseases, and Bioengineering, Nanomedicine, Cancer, Car-
diovascular Diseases and Aging. The CIBERER provides a
safe haven to the best established and also for emerging
research groups working on rare diseases. Today, it is com-
prised of 62 research groups with more than 700 scientists
from 29 institutions closely collaborating with over 20 asso-
ciated clinical groups across the country. CIBERER repre-
sents a ground-breaking initiative for optimizing resources
and facilitating synergies and cooperative projects between
groups and institutions in different areas and disciplines in
the field of rare diseases and overall with University hospi-
tals across the country. The integrated research groups are
clustered in seven research programs, encompassing major
areas of national expertise (Table 1). Currently, the strate-
gic objectives of CIBERER are closely aligned with the
European Framework Programs of Horizon 2020 in the fol-
lowing manners: (1) applying next generation sequencing
tools to the diagnosis and novel gene identification for
monogenic diseases, while generating new tools for
improving WES and WGS (Ayuso et al. 2013; Tort et al.
2013; de Castro-Miro et al. 2014; Almoguera et al. 2015;
Caparros-Martın et al. 2015; Codina-Sola et al. 2015; Asen-
cio et al. 2016; Iba~nez et al. 2016; Sevilla et al. 2016); (2)
developing novel gene and cell therapies for treating genetic
diseases (Rıo et al. 2014; Sobrevals et al. 2014; Garcıa-
Gomez et al. 2016); (3) generating patient registries of
international relevance, such as E-IMD, E-HOD, Wolfram,
McArdle, Neuromuscular Diseases, and Cushing. In this
field, CIBERER is improving the registries because it is act-
ing as an institutional umbrella for many clinical Spanish
groups; (4) promoting Orphan Drug Designation, such as
for MNGIE, Fanconi Anemia, pyruvate kinase deficiency,
and adrenoleukodystrophy; (5) hiring promising graduates
to pursue a PhD in the field of rare inherited diseases; and
(6) fostering participation in international consortiums,
such as IRDiRC, ORPHANET, EUCERD Joint Action, and
the RD Action. Nine years after its inception, CIBERER has
emerged as a key player in bringing momentum and
dynamics to novel discoveries and translation into clinical
solutions. A significant increase in the number and quality
of publications achieved by its integrating teams in the past
few years (2011–2014) serves as proof of this concept
(Fig. 2). It is notable that these achievements have been
performed with a modest annual budget of 4.7M € in 2015,
notably downsized from the initial budget of 8M € in 2008.
Underscoring the major emphasis on genomic medicine, in
2014 CIBERER developed CIBERes, or CIBERER Spanish
Variant Server (CSVS), a free online tool designed to
improve the selection of potentially pathogenic genetic
variants observed in Spanish individuals based on a reposi-
tory of Spaniards exomes. Furthermore, in 2015, CIBERER
launched two novel programs: (1) SPANEX, a web-based
database including the genomic variants (basically SNPar-
rays and exomes) of 1000 healthy aged Spanish people. This
is expected to be of highest utility for the prioritization and
clinical interpretation of variants resulting from WES and
WGS of individuals of Spanish ancestry (Dopazo et al.
2016), as this population is underrepresented in the present
publically available databases, such as 1000Genomes, ExAC,
and EVS. In addition to the development of algorithms for
variant prioritization, SPANEX aims to establish a reference
population with well-selected controls to be used for
current and future research studies, such as
Table 1. Organization of research groups per area within the
CIBERER consortium.
Research programs
Genetic medicine 12 research groups
Inherited metabolic medicine 12 research groups + 6 ACG
Mitochondrial and neuromuscular
medicine
12 research groups
Pediatric and developmental medicine 8 research groups + 4 ACG
Sensorineural pathology 7 research groups
Endocrine medicine 4 research groups + 5 ACG
Inherited cancer, hematological
and dermatological diseases
7 research groups + 5 ACG
ACG, associated clinical groups.
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pharmacogenomics, haplotype segregation, susceptibility
studies, migrations, founder effects, and evolutionary
genetics. This dataset will also provide a reference for other
populations with important Iberian contributions, such as
Latin-American populations; and (2) EnoD, a platform of
experts of different clinical and molecular specialties aiming
to investigate and help in the reinterpretation of complex,
unsolved cases after inconclusive WES results.
These initiatives are pivotal in these early times of imple-
mentation of WES as a first-tier diagnostic tool. We expect
that the favorable cost-efficiency analysis of NGS technolo-
gies and their pivotal role in diagnosis and novel gene iden-
tification (Yang et al. 2013; Solomon et al. 2016; Stark et al.
2016) will help authorities in rational decision making when
covering costs through the National Health System.
Perspectives: Integrating Research
and Clinical Genetics in Genomic
Centers
Many countries have recently made the decision to
“transform” reference Clinical Genetic services into large
Genomic Centers with the aim not only to absorb and
handle the huge number of patients’ evaluations and
genetic/genomic studies but also their growing complex-
ity. Thus, The Department of Health of the United King-
dom set up “Genomics England” in 2013 (http://
www.genomicsengland.co.uk). The aim is to deliver the
100,000 Genomes Project. Genomics England is a com-
pany owned by the Department of Health in which the
Secretary of State is the only shareholder. They work with
a range of partners (NHS England, Health Education
England, Public Health England, and 85 NHS Trusts and
hospitals across England) to deliver this project. To iden-
tify and enroll participants for the 100,000 Genomes Pro-
ject they have created NHS Genomic Medicine Centers
(GMCs). Thirteen GMCs have been established by NHS
England. Each center includes several NHS Trusts and
hospitals. GMCs recruit and consent patients. They then
provide DNA samples and clinical information for analy-
sis. These centers not only are leading the way in deliver-
ing the 100,000 Genomes Project but also have
established a clinical network for Genomic Medicine in
all the country; in other words, they have set up the bases
Figure 2. Scientific publications of CIBERER (2006–2014). Important increases in the number and impact factor publications of the research
groups comprising CIBERER since its inception, underscoring the value of collaboration and structure. D1: first decile, Q1: first quartile, Q2:
second quartile.
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for an organization of Genetics/Genomics for all patients
in UK. Similarly, other countries such as Italy, France,
and Germany have followed the UK and are currently
planning to organize the management of genetic and rare
diseases in a nation-wide fashion.
In a similar manner, in Spain the CIBERER (through
the National Plan for Rare Diseases) and many research-
ers have made recommendations to the Ministry of
Health to facilitate the creation and promotion of Geno-
mic Centers following this model. The preliminary draft
for the implementation of 4–5 Genomic Centers for all
the country is currently under evaluation. This plan
should also be approved (and more importantly, exe-
cuted) by the regional health systems of each AC, who
are nowadays facing severe budgetary restrictions, a fact
that might hinder its actual implementation nation-wide.
Concluding Remarks
Spain has excellent standards in public medical care com-
parable with those of the most advanced economies in
Europe. The previous two decades have been character-
ized by steady improvements in technological develop-
ment for research and diagnostics in clinical genomics, as
a part of a continuum. Together, the development of
strategies and initiatives at the regional and national
levels; the approval of the Clinical Genetics specialty; the
empowerment of patients, nicely exemplified by FEDER
(Federacion Espa~nola de Enfermedades Raras, www.enfer-
medades-raras.org); and the increasing awareness of the
ethical, legal, and social aspects of genetics are helping
translate the newest advances to clinical practice. The
Spanish society, today better educated than ever, places a
great value on human rights. In this sense the task in the
field of biomedicine and biology developed by the
Bioethics and Law Observatory and UNESCO Chair in
Bioethics from the Barcelona University (www. bioeticay-
derecho.ub. edu) and the Inter-University chair in Law
and the Human Genome of Universidad de Deusto and
Universidad del Paıs Vasco (www.catedraderechoygenom-
ahumano.es) has fostered a rigorous and cross-disciplin-
ary analysis of the legal implications of the advances in
molecular genetics and genomics.
One difficulty, however, is the effect that the recent
economic turmoil may exert on public and universal
access to the highest quality services in genetics and geno-
mic medicine. Nevertheless, we trust in the recognition
by law of the fundamental right of citizens to access the
best standard of care derived from the advances driven by
the novel genetic technologies and knowledge in medical
genomics. Fortunately, implementing NGS technologies
in clinical genetics practice serves two masters, improv-
ing diagnostic efficacy and thus patient management,
while saving significant costs to the public National
Health System.
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Notes
1. This denomination refers to the short period of
restored democracy in Spain. Whereas it is clear that the
origin was after Franco’s death in November 1975, the
end of this period is not clear. Some historians place it at
the Spanish Constitution in 1978 and others at the
national socialist victory (PSOE) in October 1982.
2. This name refers to the Borbon Restoration that began
in 1874 and ended with the proclamation of the Second
Spanish Republic in 1931.
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